Related Experiment Video
Updated: Aug 6, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
In vitro tau fibrillization: mapping protein regions
Ismael Santa-María1, Mar Pérez, Félix Hernández
1Centro de Biología Molecular "Severo Ochoa" CSIC/UAM, Fac. Ciencias, Facultad de Ciencias, Campus de Cantoblanco, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain.
Biochimica Et Biophysica Acta
|August 8, 2006
Summary
Tau protein aggregation is crucial for neurodegenerative diseases. This study identifies key residues (305-335) essential for tau fibril formation, with modifications impacting aggregation propensity.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Tau protein aggregation into fibrils is a hallmark of neurodegenerative diseases like Alzheimer's.
- Understanding the molecular mechanisms of tau fibrillization is critical for developing therapeutic strategies.
Purpose of the Study:
- To investigate the fibrillization propensity of tau protein fragments and variants.
- To identify specific regions (hotspots) critical for tau aggregation.
- To assess the impact of post-translational modifications on tau fibril formation.
Main Methods:
- Utilized coenzyme Q(0) as a tau fibrillization inducer.
- Compared polymerization propensity of tau fragments with corresponding deleted variants.
- Examined the effects of phosphorylation and deamidation on tau aggregation.
Main Results:
- Residues 305 to 335 were identified as essential for in vitro tau fibrillization.
- Residues 306 to 311 were found to facilitate in vitro assembly but not fully mimic in vivo fibrillization.
- Chemical modifications of tyrosine 310, common in vivo, significantly decreased the fibril-forming propensity of the 306-311 sequence.
Conclusions:
- The region 305-335 of tau protein is critical for in vitro fibril formation.
- Specific sequences like 306-311 play a role in assembly, but in vivo relevance is modulated by modifications.
- Post-translational modifications, such as those at tyrosine 310, can significantly alter tau aggregation pathways.
